At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
BMS-986259 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure
In Brief
A Phase 2 clinical trial evaluating BMS-986259 and Placebo for Acute Decompensated Heart Failure. Completed, enrolled 25 participants across 18 sites in 6 countries.
Detailed Summary
The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Decompensated Heart Failure
CountriesArgentina, Czechia, Greece, Israel, Poland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartNov 2020
Primary CompletionJul 2021
TodayJul 2026
First PostedMar 23, 2020
Enrollment StartNov 6, 2020
Primary CompletionJul 19, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.3 years ago
Interventions
BMS-986259drug
Specified dose on specified days
Placeboother
Specified dose on specified days